PALVELLA THERAPEUTICS, INC. PVLA

Rank #1599 · Nasdaq · $2.1B market cap

Audited by Ernst & Young LLP, no going-concern flag in the latest filing.

Score

45.8

P/E

-120.2

P/B

-28.14

ROE

23.4%

Op. Margin

–%

Debt Ratio

-34%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -120.2x, P/B -28.14x. Ranks in the top 84% of the universe.

Profitability ★★★★☆

Excellent

ROE 23.4%. Ranks in the top 19% of the universe.

Safety ★★★★★

Excellent

Debt ratio -34%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2014	$0.0B	$0.0B	$0.0B	$0.0B	4.5	1350
2015	$0.0B	$-0.0B	$-0.0B	$0.0B	-134.2	658
2016	$0.0B	$-0.0B	$-0.0B	$0.0B	-466.6	16
2017	$0.0B	$-0.0B	$-0.0B	$0.0B	-390.3	32
2018	$0.0B	$-0.0B	$-0.0B	$0.0B	-57.7	366
2019	$0.0B	$-0.0B	$-0.0B	$0.0B	-105.9	880
2020	$0.0B	$-0.0B	$-0.0B	$0.0B	-58.7	225
2021	$0.0B	$-0.0B	$-0.0B	$0.1B	-115.7	144
2022	$0.0B	$-0.1B	$-0.0B	$0.0B	-165.0	331
2023	$0.0B	$-0.0B	$-0.0B	$0.1B	-167.8	133
2024	–	$-0.0B	$0.0B	$-0.1B	–	-12
2025	–	$-0.0B	$-0.0B	$-0.1B	–	-34